Recent Updates
Recently added Catalysts
IONS

Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS

Friday, December 11, 2015 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.1%
average across 11 past catalysts
Lead asset
ISIS 113715
Phase 2 · Type 2 Diabetes Mellitus

Full Press Release Details

Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS.
ShareAdd on Google
Tags: IONS Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Dec 11, 2015

Biotech snapshot

Cash runway
$2702M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ISIS 113715Phase 2
Type 2 Diabetes Mellitus →

Catalyst track record

+24%
best trade around IONS's most recent catalyst

Peak hindsight return over a 120-day window, across 11 tracked FDA/PDUFA catalysts for IONS.

See every catalyst's timing & PoA →